Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.15967 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concurrent Viewing of H&E and Multiplex Immunohistochemistry in Clinical Specimens.
Diagnostics (Basel)
January 2025
Roche Diagnostics Solutions (Ventana Medical Systems, Inc.), 1910 E. Innovation Park Dr., Tucson, AZ 85755, USA.
Performing hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) on the same specimen slide provides advantages that include specimen conservation and the ability to combine the H&E context with biomarker expression at the individual cell level. We previously used invisible deposited chromogens and dual-camera imaging, including monochrome and color cameras, to implement simultaneous H&E and IHC. Using this approach, conventional H&E staining could be simultaneously viewed in color on a computer monitor alongside a monochrome video of the invisible IHC staining, while manually scanning the specimen.
View Article and Find Full Text PDFTargeted immunotherapy in the treatment of childhood and adolescent classic Hodgkin lymphoma.
Clin Adv Hematol Oncol
December 2024
Department of Pediatrics, New York Medical College, Valhalla, New York.
Childhood and adolescent classic Hodgkin Lymphoma (cHL) has long been a model for how we balance improved outcomes with increased toxicities in pediatric cancer. The recognition that unacceptable short- and long-term toxicities come with increasing intensity of treatment has led to a decades-long attempt to better understand the patient-specific factors that dictate responses and outcomes. Targeted immunotherapy has emerged as a promising adjunct to cancer treatment; it has been shown to improve outcomes for poorly responding patients, to salvage relapsed disease, and more recently, to replace more toxic therapy modalities such as chemotherapy and radiation while maintaining excellent outcomes.
View Article and Find Full Text PDFPhase 2 Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1 Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.
Clin Cancer Res
December 2024
Baylor University Medical Center, Dallast, Texas, United States.
Purpose: Brentuximab vedotin (BV) is hypothesized to selectively deplete T regulatory cells (Tregs) that express CD30 and re-sensitize tumors to anti-(PD-1) therapy. This study evaluated responses to BV+pembrolizumab post PD-1 and explored corresponding biomarkers.
Methods: 55 patients with metastatic non-small cell lung cancer (NSCLC) and 58 with metastatic cutaneous melanoma received ≥1 dose of BV+pembrolizumab.
Application of deep learning models on single-cell RNA sequencing analysis uncovers novel markers of double negative T cells.
Sci Rep
December 2024
Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, VA, USA.
Double negative T (DNT) cells are a unique subset of CD3 + TCRαβ + T lymphocytes that lack CD4, CD8, or NK1.1 expression and constitute 3-5% of the total T cell population in C57BL/6 mice. They have increasingly gained recognition for their novel roles in the immune system, especially under autoimmune conditions.
View Article and Find Full Text PDFIdentifying potential drug targets for myocardial infarction through Mendelian randomization.
PLoS One
December 2024
Department of Cardiology, Shaanxi Provincial People's Hospital, Xi'an, P. R. China.
Background: This study explored the associations between plasma and cerebrospinal fluid (CSF) proteins and myocardial infarction (MI) risk. Identifying specific proteins as biomarkers for MI could enhance our understanding of disease mechanisms and inform clinical practice.
Methods: We combined protein quantitative trait loci (pQTL) data for plasma and CSF proteins with genome-wide association study (GWAS) summary statistics for MI.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!